Celgene (CELG) Tops Q1 EPS by 9c, Updates Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. SPY
3. GLOB
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DGNX

May 4, 2018 7:31 AM EDT

Celgene (NASDAQ: CELG) reported Q1 EPS of $2.05, $0.09 better than the analyst estimate of $1.96. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.46 billion.

Celgene Expects Volume-Driven Product Sales and Earnings Growth in 2018

Previous 2018 Guidance* Updated without dilution from Juno Updated with dilution from Juno
Total Revenue $14.4B to $14.8B ~$14.8B ~$14.8B
REVLIMID® Net Product Sales ~ $9.4B ~ $9.5B ~ $9.5B
POMALYST®/IMNOVID® Net Product Sales ~ $1.9B ~ $2.0B ~ $2.0B
OTEZLA® Net Product Sales ~ $1.5B Unchanged Unchanged
ABRAXANE® Net Product Sales ~ $1.0B Unchanged Unchanged
GAAP Operating Margin ~ 46.5% ~ 45% ~ 38%
GAAP Diluted EPS $7.26 to $7.66 ~ $7.36 ~ $6.31
Adjusted Operating Margin

Adjusted Diluted EPS

 ~ 60.0%

$8.70 to $8.90

 Unchanged

~$8.95

 ~56.0%

~$8.45

Adjusted Tax Rate ~18% ~17.5% ~17%
Weighted Average Diluted Shares ~ 775M ~755M ~755M

* Previous 2018 guidance did not include the impact of our acquisition of Juno, which was expected to be dilutive to adjusted diluted EPS in 2018 by approximately $0.50.

(Street sees FY EPS of $8.46 on revenue of $14.81 billion)

For earnings history and earnings-related data on Celgene (CELG) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance

Related Entities

Earnings, Definitive Agreement